CTNM Heads Into Earnings With Shorts Doubling Down and Options Heavily Skewed

Contineum Therapeutics reports after the close today with short sellers having doubled their exposure over the past month while options traders stack puts at a ratio well above recent norms — making this one of the more charged setups in small-cap biotech ahead of the print.

The clearest tension sits in the short interest data. Bears have been aggressive: short interest climbed 75% over the past month to reach 10.6% of the free float, with another 14% added in the last week alone. The move is notable because it happened against a rising stock — shares gained 10% over the past week to close at $15.75, suggesting active short-sellers are pressing into strength rather than chasing a falling name. The borrow market, however, does not corroborate a squeeze setup. Availability is wide at roughly 987% of outstanding short interest, meaning there are nearly ten shares available to borrow for every one already shorted. Cost to borrow remains negligible at 0.61%. Bears are building positions without friction.

Options positioning tells the same cautious story. The put/call ratio has climbed to 4.34 — well above its 20-day average near 2.66 and approaching the 52-week high of 5.02. That ratio reflects heavy demand for downside protection relative to calls, and it jumped sharply in the week of July 21 from levels below 0.5, suggesting a meaningful shift in sentiment around a specific catalyst. The z-score of 1.3 confirms the skew is elevated but not yet extreme by historical standards.

The bull and bear cases are firmly clinical. Bulls point to a cash runway of $190.7 million extending through 2027, solid early-stage pharmacokinetics for PIPE-791 and PIPE-307, and substantial unmet need in multiple sclerosis. The most recent analyst moves — both over two months old — saw Morgan Stanley lift its target to $16 in May while keeping an Equal-Weight rating, and Baird raise to $20 in March with an Outperform. The consensus target of $22.86 sits 45% above the current price, suggesting the Street as a whole sees meaningful upside. Bears counter with the absence of any revenue, the execution risks of advancing both candidates into Phase II, and commercial uncertainty around PIPE-791 given its partnership structure with Johnson & Johnson. The stock's prior event reactions have been uneven: a 12% jump after the June 26 update, a 3% drop after the May 14 release, and a 6% gain after May 5 — no consistent directional pattern.

One structural wrinkle worth noting: insider selling has been consistent throughout June and early July, with the CEO, CSO, and CMO all reducing positions at prices around $16. The net 90-day insider sale total reaches roughly $1.1 million — modest in dollar terms but broad in participation across the C-suite. Separately, BlackRock added 1.38 million shares as of June 30, a material new position that represents the most active institutional move in the recent filing cycle.

The print will test whether PIPE-791 or PIPE-307 clinical updates justify the short-seller conviction that has built steadily into the event — or whether the Street's price-target premium above current levels reflects a more optimistic read on the data.